EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy

Laura Denisa Dragu iD, Mihaela Chivu-Economescu iD, Ioana Madalina Pitica iD, Lilia Matei iD, Coralia Bleotu iD, Carmen Cristina Diaconu iD, Laura Georgiana Necula

Current Issues in Molecular Biology · 08.07.2025 · 47 (7) · 525

DOI: 10.3390/cimb47070525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 08.07.2025. Verfasst von Laura Denisa Dragu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, and The Romanian Academy, The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, The Romanian Academy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This manuscript assesses the critical role of exosomal PD-L1 (ExoPD-L1) in immune suppression, tumor progression, and resistance to therapy. ExoPD-L1 has been identified as a key mediator of tumor immune evasion, contributing to systemic immunosuppression beyond the tumor microenvironment (TME) due to its capacity to travel to distant anatomical sites. In this context, the review aims to elaborate on the mechanisms by which exosomal PD-L1 interacts with T cell receptors and modulates both the tumor microenvironment and immune responses, impacting patient outcomes. We further explore emerging therapeutic strategies that target ExoPD-L1 to enhance the effectiveness of immunotherapy. Blocking ExoPD-L1 offers a novel approach to counteracting immune escape in cancer. Promising strategies include inhibiting exosome biogenesis with GW4869 or Rab inhibitors, neutralizing ExoPD-L1 with targeted antibodies, and silencing PD-L1 expression through RNA interference (RNAi) or CRISPR-based methods. While each approach presents certain limitations, their integration into combination therapies holds significant potential to improve the efficacy of immune checkpoint inhibitors. Future research should focus on optimizing these strategies for clinical application, with particular attention to improving delivery specificity and minimizing off-target effects.

Schlagwörter

Stichwörter der Autor:innen

ExoPD-L1cancer immunotherapyexosomeimmune evasiontherapy resistance

Autor:innen und Institutionen

  • Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
  • Faculty of Medicine, Titu Maiorescu University, 040051 Bucharest, Romania.

ORCID-Profile: Laura Denisa Dragu, Mihaela Chivu-Economescu, Ioana Madalina Pitica, Lilia Matei, Coralia Bleotu, Carmen Cristina Diaconu

Förderung

  • The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, and The Romanian Academy
  • The Ministry of Investments and European Projects, through the Managing Authority for the Health Program
  • The Romanian Academy

Zitieren

APA

Dragu, L. D., Chivu-Economescu, M., Pitica, I. M., Matei, L., Bleotu, C., Diaconu, C. C., & Necula, L. G. (2025). Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy. Current Issues in Molecular Biology, 47(7), 525. https://doi.org/10.3390/cimb47070525

Vancouver

Dragu LD, Chivu-Economescu M, Pitica IM, Matei L, Bleotu C, Diaconu CC, et al. Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy. Current Issues in Molecular Biology. 2025;47(7):525. doi:10.3390/cimb47070525

BibTeX
@article{Dragu2025,
  author = {Dragu, Laura Denisa and Chivu-Economescu, Mihaela and Pitica, Ioana Madalina and Matei, Lilia and Bleotu, Coralia and Diaconu, Carmen Cristina and Necula, Laura Georgiana},
  title = {Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy},
  journal = {Current Issues in Molecular Biology},
  year = {2025},
  volume = {47},
  number = {7},
  pages = {525},
  doi = {10.3390/cimb47070525}
}
Kostenlos starten →